Historical Stock Chart
2 Months : From Feb 2020 to Apr 2020
By Michael Dabaie
Amgen Inc., Cytokinetics Inc. and Servier said they would continue the GALACTIC-HF Phase 3 heart failure trial following a planned interim analysis.
The companies said the Data Monitoring Committee recommended the Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure continue without changes.
Topline results are expected in the fourth quarter of 2020.
GALACTIC-HF completed enrollment of more than 8,200 patients in 35 countries who were either hospitalized at the time of enrollment for a primary reason of heart failure, or had a hospitalization or admission to an emergency room for heart failure within one year prior to screening.
Omecamtiv mecarbil is being developed by Amgen in collaboration with Cytokinetics, with funding and strategic support from Servier.
Write to Michael Dabaie at email@example.com
(END) Dow Jones Newswires
February 26, 2020 09:49 ET (14:49 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.